Millennium Management LLC Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Millennium Management LLC reduced its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 71.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,196 shares of the biopharmaceutical company's stock after selling 55,734 shares during the period. Millennium Management LLC's holdings in Agios Pharmaceuticals were worth $729,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Jefferies Financial Group Inc. acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $49,290,000. Adage Capital Partners GP L.L.C. acquired a new position in Agios Pharmaceuticals during the 4th quarter valued at about $9,957,000. Deutsche Bank AG increased its holdings in Agios Pharmaceuticals by 39.7% during the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after purchasing an additional 265,637 shares in the last quarter. Casdin Capital LLC purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $8,215,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $8,151,000.

Insider Transactions at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded up $0.85 during mid-day trading on Tuesday, reaching $34.51. 623,874 shares of the company's stock were exchanged, compared to its average volume of 666,603. The firm has a 50-day moving average price of $29.22 and a two-hundred day moving average price of $34.08. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of 3.04 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on AGIO shares. HC Wainwright started coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Finally, Scotiabank cut their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $56.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.